Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Shares of Xencor, Inc. are down nearly 6% after the company announced Novartis terminated its rights to develop vibecotamab, a CD123 x CD3 blood cancer bispecific.
Although Martin Shkreli continues to serve a prison sentence for fraud, the so-called “Pharma Bro” remains in legal hot water over antitrust charges.
Biohaven and Pfizer have partnered to market the Nurtec migraine medicine outside the U. S. once approved by global regulatory organizations. Here’s more about it.
Sungho Han, Ph.D., founder and CEO of Genuv Inc. in Seoul, South Korea, has built her career and her company by thinking outside the box.
Alltrna, based in Cambridge, Mass. near its cousin Moderna, debuts as the first platform transfer RNA (tRNA) company.
Autolus is currently working on advancing obecabtagene autoleucel, its CD19 CAR T cell investigational therapy product candidate, in addition to other applications of obe-cel in B-cell malignancies.
The $80 million infusions from ATP will advance Marengo’s lead candidate, STAR0602, which aims to treat advanced and metastatic solid tumors.
Kindness. Respect. Innovation. Only one of those words typically features in biotech mission statements, but at Ikena Oncology, all three are important – and have been from day one.
bluebird bio has completed the spin-off of its oncology programs into the new business entity, 2seventy bio, Inc, which will begin trading on the Nasdaq this morning under the ticker symbol “TSVT.”
The first week of November was marked by numerous clinical trial announcements. Here’s a look.